ST. Louis-A St. Louis start-up company has obtained a license for the COVID-19 vaccine developed by the University of Washington.
According to our partners after the assignment, Precision Virologics has obtained the right to use the Wash U vaccine in the United States, Europe and Japan. The company is also developing vaccines against other diseases, including the mosquito-borne Zika virus.
Experts say that it is not the first vaccine on the market, but it has an advantage over other competitors.
This is a nasal spray rather than an injection, and it seems to destroy any coronaviruses that may already be present. So far, the Washington U. vaccine has only been tested in mice. They hope that human trials will begin next spring.